Retatrutide approximately doubles the weight loss achieved with semaglutide across comparable timeframes and trial designs
Pickart L, Thayer L, Thaler MM
Abstract Background and Objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes
Boswellic acid counters the action of cytokines involved in tissue damage due to inflammation such as IL-1, IL-2, INF-, and TNF-
Naturally flavoured, vegan-friendly and sugar-free, this liposomal blend offers a convenient and enjoyable way to support daily wellbeing
doi: 10.1016/j.tem.2018.09.001 32 PaniAGiossiRMenichelliDFittipaldoVAAgnelliFIngleseEet al